Baricitinib for the Treatment of Alopecia Areata

    May 2023 in “ Drugs ”
    Egídio Freitas, Emma Guttman‐Yassky, Tiago Torres
    Studysummary This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 29

    1. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
    2. Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2022
    3. Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials British journal of dermatology/British journal of dermatology, Supplement · 2022
    4. Analysis of Alopecia Areata Surveys Suggests a Threshold for Improved Patient-Reported Outcomes British Journal of Dermatology · 2022
    5. Baricitinib in Alopecia Areata New England Journal of Medicine · 2022
    6. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    7. Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial Journal of the American Academy of Dermatology · 2021
    8. Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2021
    9. Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study Journal of The American Academy of Dermatology · 2021
    10. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    11. Alopecia Areata: A Complex Cytokine-Driven Disease ˜The œjournal of investigative dermatology. Symposium proceedings/˜The œJournal of investigative dermatology symposium proceedings · 2020
    12. ‘You Lose Your Hair, What’s the Big Deal?’ I Was So Embarrassed, I Was So Self-Conscious, I Was So Depressed: A Qualitative Interview Study to Understand the Psychosocial Burden of Alopecia Areata Journal of Patient-Reported Outcomes · 2020
    13. IL-12/IL-23 Neutralization Is Ineffective for Alopecia Areata in Mice and Humans ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2019
    14. The Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata: A Systematic Review Dermatologic therapy · 2019
    15. JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2019
    16. Treatment of Alopecia Areata: An Australian Expert Consensus Statement Australasian journal of dermatology · 2018
    17. JAK Inhibitors for Treatment of Alopecia Areata ˜The œjournal of investigative dermatology/Journal of investigative dermatology · 2018
    18. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis Journal of Investigative Dermatology · 2018
    19. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents Journal of Investigative Dermatology Symposium Proceedings · 2017
    20. Alopecia Areata: Treatment Options and Efficacy Journal of the American Academy of Dermatology · 2017
    21. The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm Advances in Therapy · 2017
    22. Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents Journal of the American Academy of Dermatology · 2016
    23. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
    24. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    25. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    26. Familial Aggregation of Alopecia Areata Journal of the American Academy of Dermatology · 2016
    27. Epidemiology and Burden of Alopecia Areata: A Systematic Review Clinical, Cosmetic and Investigational Dermatology · 2015
    28. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    29. Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity Nature · 2010

    Related research 3

    1. Alopecia Areata: A Multifactorial Autoimmune Condition Journal of autoimmunity · 2018
    2. Linear Alopecia Areata JAAD case reports · 2018
    3. Treating Resistant Cases of Alopecia Universalis Journal of cosmetology & trichology · 2018